Taliglucerase Alfa, Recombinant β-glucocerebrosidase

Specification

• Cat#: THP-0094
• Product Name: Taliglucerase Alfa, Recombinant β-glucocerebrosidase
• Description: The product is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase.
• Sequences: Not Available
• Species: Human
• Molecular Weight: 56637.9397 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 37228-64-1
• Formula: C2580H3918N680O727S17
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 200U/5ml

Pharmaceutical Information

• Pharmaceutical Application: Taliglucerase Alfa
• Applications: For the treatment of adult Type 1 Gaucher disease.
• Examples of Clinical Use: Type 1 Gaucher disease
• Pharmacodynamics: Patient's with Type 1 Gaucher disease have a long-term deficiency in the enzyme, glucocerebrosidase. The product is a modified form of glucocerebrosidase and is provided to counter this enzyme deficiency, resulting in smaller liver and spleen size, and improved thrombocytopenia and anemia.
• Mechanism of action: Taliglucerase alfa is different from human glucocerebrosidase by two amino acids at the N terminal and up to 7 amino acids at the C terminal. This recombinant enzyme allows the hydrolysis reaction of glucocerebroside to glucose and ceramide that naturally occurs in healthy individuals.
• Affected organisms: Humans and other mammals